Evaluate the Safety and Feasibility of tACS With the Miamind Neurostimulator in Healthy Participants

NACompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

December 27, 2023

Primary Completion Date

March 22, 2024

Study Completion Date

March 22, 2024

Conditions
Healthy ParticipantsHealthy Population
Interventions
DEVICE

Personalized Miamind Neurostimulator

60 min. 40 Hz max. 1mA / electrode \& total of max. 2 mA across all electrodes. 30- s ramp-up personalised intervention based on individual modelling of electric field distribution to maximise therapeutic effect in the target region. Three target regions, consecutively stimulated (20min each).

Trial Locations (1)

4031

Universitätsspital Basel, Basel

All Listed Sponsors
collaborator

Hemex AG

INDUSTRY

lead

Bottneuro AG

INDUSTRY

NCT05999916 - Evaluate the Safety and Feasibility of tACS With the Miamind Neurostimulator in Healthy Participants | Biotech Hunter | Biotech Hunter